Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.

Hoebers, Frank J. P.; Pameijer, Frank A.; de Bois, Josien; Heemsbergen, Wilma; Balm, Alfons J. M.; Schornagel, Jan H.; Rasch, Coen R. N.

Background. The purpose of this study was to evaluate the prognostic value of tumor volume in head and neck squamous cell carcinoma treated with chemoradiation. Methods. Forty-six patients were treated with radiotherapy and cisplatin (6 mg/m2 IV x20, daily). Baseline primary tumor volume was recorded from MRI scans. The prognostic impact of tumor volume and other factors for locoregional control, disease-free survival (DFS), and overall survival (OS) was tested. Results. Mean tumor volume was 28 cm3 (median 23 cm3; range, 3–112). The locoregional control rate at 3 years was 81% for patients with tumor volumes <median compared to 48% for tumor volumes ≥ median (p = .036). At multivariate analysis, it appeared that tumor volume remained an independent determinant of locoregional control and survival when adjusted for other factors. Conclusions. In advanced-stage head and neck squamous cell carcinoma treated with concurrent chemoradiation, primary tumor volume is associated with locoregional control and survival. Larger studies are needed to confirm whether incorporation of tumor volume in the staging system improves prediction of treatment outcome and can serve as a tool to guide treatment options. © 2008 Wiley Periodicals, Inc. Head Neck 2008

HEAD & neck cancer; CISPLATIN; TUMORS; PROGNOSTIC tests; SQUAMOUS cell carcinoma

Head & Neck, 2008, Vol 30, Issue 9, p1216

1043-3074

Academic Journal

10.1002/hed.20865